Global Microphysiological System and Organoids Market Strategic Research Report

Scope of the Report

The global Microphysiological System and Organoids market size is predicted to grow from US$ 147 million in 2025 to US$ 428 million in 2032; it is expected to grow at a CAGR of 16.8% from 2026 to 2032.

Microphysiological systems (MPS), also known as organ-on-a-chip systems, and organoids are innovative technologies used in biomedical research to model human physiology and diseases in vitro. MPS are microscale platforms that mimic the structure and function of human organs or tissues, typically incorporating cells, scaffolds, and microfluidic channels to create microenvironments that replicate physiological conditions. Organoids, on the other hand, are three-dimensional clusters of cells grown from stem cells or tissue samples that self-organize and differentiate into structures resembling specific organs. These systems offer unique advantages for studying human biology and disease mechanisms, enabling researchers to recapitulate complex tissue architecture and cellular interactions in a controlled laboratory setting. MPS and organoids hold great promise for drug discovery, toxicity testing, disease modeling, and personalized medicine applications, facilitating the development of more effective therapies and treatments.

The global key companies of Microphysiological System include Emulate, Mimetas, InSphero, TissUse, CN Bio, Valo Health (TARA Biosystems), Hesperos, TNO, 28bio, Newcells Biotech, etc. In 2024, the global five largest players hold a share approximately 48.81% in terms of revenue.

Due to better policy and financial support in European countries and USA and earlier research, the overall industry of microphysiological system has developed rapidly, and the industrialization process in other regions such as Asia is lagging behind.

It is worth noting that because the microphysiological system industry is still in the early stages of development, and the mid-stream and downstream demand has not yet increased, many microphysiological system companies play an upstream role to some extent and mostly conduct organoid and organ-on-chip research on their own. Research and development of chip automation, high-throughput operating instruments and imaging equipment.

With the further development of the industry in the future and the implementation of relevant policies and standards, the industry's demand for upstream will increase, which will promote the birth of more professional upstream companies and the business transformation of some microphysiological system companies.

This report presents a comprehensive overview of the global Microphysiological System and Organoids market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Human Organ and Tissue Models
• Disease Models
• Non-Human Species Models

Segment by Application

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Microphysiological System and Organoids market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact